{"disease":{"id":"non-metastatic-castration-resistant-prostate-cancer-nmcrpc","name":"non metastatic castration resistant prostate cancer nmcrpc"},"drugs":{"marketed":[{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"darolutamide","guideline_body":"FDA label","recommendation":"NUBEQA is indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"darolutamide","guideline_body":"FDA label","recommendation":"NUBEQA is indicated for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"darolutamide","guideline_body":"FDA label","recommendation":"NUBEQA is indicated for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}